GlassScriptPhysician profile
Jose F Ramirez
NPI 1073553780
$7,601.11
in general payments reported to CMS, 2019-2025
33 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $1,211 · 2021: $401 · 2022: $1,237 · 2023: $1,898 · 2024: $1,280 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,427 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,426.83 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $1,667.78 | 2020-2025 | Wakix |
| Genentech, INC. | $1,000.00 | 2020 | |
| Glaxosmithkline, LLC. | $979.71 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $760.21 | 2020-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.29 | 2020-2025 | Ofev, Spiriva, Stiolto Respimat |
| Mylan Specialty L.P. | $295.69 | 2021-2024 | Yupelri |
| Genzyme Corporation | $295.22 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $254.35 | 2021-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $252.76 | 2022-2025 | Acthar |
| Amgen INC. | $224.75 | 2022-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $172.31 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $93.92 | 2023 | Quviviq |
| Insmed, INC. | $82.83 | 2022-2025 | Arikayce |
| Verona Pharma, INC. | $82.48 | 2025 | Ohtuvayre |
| Fisher & Paykel Healthcare INC | $79.53 | 2023-2024 | Fisher & Paykel Healthcare |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $76.10 | 2019 | |
| Viatris Specialty LLC | $70.94 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $65.22 | 2024-2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $64.16 | 2019-2025 | |
| Baxter Healthcare | $58.10 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $54.19 | 2019 | |
| Shire North American Group INC | $53.62 | 2019 | |
| Electromed, INC. | $43.43 | 2022-2025 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $41.93 | 2021 | |
| Resmed Corp | $33.53 | 2023 | |
| Grifols USA, LLC | $33.40 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $33.32 | 2024-2025 | Lumryz |
| Biotronik INC. | $28.78 | 2022 | |
| Optinose US, INC. | $23.13 | 2025 | |
| Nabriva Therapeutics, Plc | $23.10 | 2022 | |
| Pfizer INC. | $21.18 | 2023 | |
| Lilly USA, LLC | $19.39 | 2025 | Zepbound |
| United Therapeutics Corporation | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.